Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

1. FDA suspended Valneva's Ixchiq license due to serious adverse events. 2. Ixchiq license suspension requires halt in U.S. distribution and sales. 3. Valneva's revenue remains unchanged despite potential permanent withdrawal impact. 4. Sales of Ixchiq accounted for 7.5 million euros in H1 2025. 5. Valneva received approval for Ixchiq in Canada despite U.S. suspension.